Video: Jim Cramer Reacts to Celgene's Plans to Acquire Juno Therapeutics
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts to Celgene's plans to acquire Juno Therapeutics for about $9 billion on Monday.
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts to Celgene's (CELG) - Get Report plans to acquire Juno Therapeutics (JUNO) for about $9 billion on Monday.
Want more exclusive investing insight from Jim Cramer? Get 24/7 access to Jim's charitable trust portfolio with a free trial to Action Alerts PLUS!
Watch all of Jim Cramer's full NYSE live shows right here: